The Age-related Macular Degeneration (AMD) Center of Excellence is dedicated to unraveling the complex and multifactorial causes of AMD, the leading cause of blindness in developed countries.
Patricia A. D'Amore, PhD, MBA
Deeba Husain, MD
Ivana K. Kim, MD
See a list of AMD faculty
Age-related macular degeneration (AMD) occurs in neovascular ("wet" or exudative) and nonneovascular ("dry" or nonexudative) forms, and, according to the World Health Organization, it is the leading cause of blindness in developed countries and ranks third worldwide after cataract and glaucoma.
Investigators in the center have made many groundbreaking contributions to the understanding and treatment of AMD. They pioneered the pharmacologic treatment of AMD with the development of verteporfin photodynamic therapy (Visudyne). They also identified the role of vascular endothelial growth factor (VEGF) in vascular eye disease, forming the scientific basis of current anti-VEGF therapies for neovascular AMD, diabetic macular edema, and macular edema following retinal vein occlusion.
Our researchers are currently working to advance the diagnosis, prevention, and treatment of AMD. They are studying genetic and environmental risk factors and are working to define the underlying pathophysiology with a goal of developing novel approaches to diagnosis and therapy.
The Biennial International Symposium on AMD brings together international experts from a diverse array of fields, as well as leaders from related disciplines outside ophthalmology in an interactive format to discuss current and future topics in AMD research. Learn more...